OMERS ADMINISTRATION Corp Invests $372,000 in Rezolute, Inc. (NASDAQ:RZLT)

OMERS ADMINISTRATION Corp acquired a new stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 76,000 shares of the company's stock, valued at approximately $372,000. OMERS ADMINISTRATION Corp owned about 0.13% of Rezolute as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Rezolute during the 3rd quarter worth $42,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares during the period. American Century Companies Inc. grew its holdings in Rezolute by 62.1% in the fourth quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after purchasing an additional 24,742 shares during the period. Geode Capital Management LLC increased its stake in Rezolute by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock worth $2,535,000 after acquiring an additional 25,413 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in Rezolute during the fourth quarter worth $277,000. Institutional investors own 82.97% of the company's stock.

Wall Street Analysts Forecast Growth

RZLT has been the subject of several analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Rezolute in a research note on Wednesday, May 14th. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Rezolute in a report on Monday, April 28th. Finally, JMP Securities boosted their target price on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.14.

Rezolute Trading Down 0.3%

Shares of RZLT traded down $0.01 during midday trading on Friday, reaching $3.89. The stock had a trading volume of 431,957 shares, compared to its average volume of 587,753. The firm has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $4.23. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19. The firm has a market cap of $235.48 million, a PE ratio of -3.19 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). As a group, research analysts forecast that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Nevan C. Elam purchased 12,302 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the acquisition, the chief executive officer now owns 224,119 shares in the company, valued at $638,739.15. The trade was a 5.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daron Evans purchased 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $2.89 per share, with a total value of $28,900.00. Following the acquisition, the chief financial officer now owns 237,900 shares in the company, valued at $687,531. This represents a 4.39% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 29,060 shares of company stock worth $83,694 in the last quarter. Insiders own 18.39% of the company's stock.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.